Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:
• Established diagnosis of cystic fibrosis
• Age 12 years and older
• Stable use of elexacaftor/tezacaftor/ivacaftor for 90 days prior to enrollment
• Sweat chloride concentration 50 mmol/L or greater while on elexacaftor/tezacaftor/ivacaftor
Locations
United States
Kansas
University of Kansas Medical Center
RECRUITING
Kansas City
Contact Information
Primary
Heidi Hellwig
hhellwig@kumc.edu
9135886045
Backup
Carolina Aguiar
caguiar@kumc.edu
9139459295
Time Frame
Start Date: 2024-06-03
Estimated Completion Date: 2027-10
Participants
Target number of participants: 42
Treatments
Experimental: Losartan
Losartan 25mg twice daily for one week followed by 50mg twice daily through week 12.
Placebo_comparator: Placebo
Placebo twice daily through week 12
Related Therapeutic Areas
Sponsors
Leads: University of Kansas Medical Center